The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Arm 1 will administer Libtayo on day 5. The Company plans to ... MAIA expects to conduct the trials in the U.S. and select countries in Europe and Asia. MAIA recently announced an amended clinical ...

Total Libtayo sales came in at $366.9 million ... was submitted to the FDA and a decision is expected by mid-2025. The European Commission (EC) approved Dupixent to treat eosinophilic esophagitis ...

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with cemiplimab (Libtayo ... and the European Association of Dermatology ...

With its surge over the last few years, Novo has become the highest valued biopharma company in Europe. Of the 22 biopharma ... year—and cancer treatment Libtayo, which reached blockbuster ...

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines ... which currently comprises Libtayo (cemiplimab-rwlc ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...